ANTH Anthera Pharmaceuticals, Inc.

0.66
-0.02  -2.38%
Previous Close 0.68
Open 0.68
Price To book 3.76
Market Cap 27.72M
Shares 41,955,000
Volume 730,128
Short Ratio 3.70
Av. Daily Volume 2,073,470

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 primary endpoint not met
Blisibimod
IgA nephropathy
Top-line data released December 27, 2016 - missed primary endpoint. New trial to be initiated 1Q 2017.
Sollpura (liprotamase)
Cystic fibrosis who suffer from exocrine pancreatic insufficiency
Phase 3 trial did not meet endpoints - November 10, 2016.
Blisibimod
Lupus

Latest News

  1. ANTH INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Anthera Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of April 17, 2017
  2. Johnson & Weaver, LLP Announces Investigations of Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio Corporation
  3. Robbins Arroyo LLP: Anthera Pharmaceuticals, Inc. (ANTH) Misled Shareholders According to a Recently Filed Class Action
  4. ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
  5. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Has Filed a Complaint to Recover Losses Suffered by Investors in Anthera Pharmaceuticals, Inc.
  6. Twitter, Coty, Micron Technology: Doug Kass' Views
  7. These 5 Stocks Under $10 Could Explode Up Soon
  8. Lifshitz & Miller LLP Announces Investigation of Anthera Pharmaceuticals, Inc., Arctic Cat Inc., Banc of California, Inc., Dollar General Corporation, MoneyGram International, Inc., QUALCOMM Incorporated, Stonegate Mortgage Corporation and
  9. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Anthera Pharmaceuticals, Inc. (ANTH)
  10. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Anthera Pharmaceuticals, Inc.
  11. ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure
  12. Plug Power, Innocoll Drop into Friday’s 52-Week Low Club
  13. Top Analyst Upgrades and Downgrades: Biogen, Comerica, Deere, NVIDIA, 21st Century Fox and More
  14. Anthera Pharma downgraded by Citigroup and Jefferies
  15. Anthera Pharmaceuticals downgraded at SunTrust, price target slashed to $1 from $6
  16. Anthera, Endologix Fall into Wednesday’s 52-Week Low Club
  17. Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data
  18. Anthera Pharmaceuticals Inc (ANTH) Looks Good For A Recovery
  19. ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
  20. Anthera Pharma plunges 66% after missing target in study
  21. Anthera Announces the Phase 3 SOLUTION Study with Sollpura™ in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results - Additional Study Needed
  22. Anthera Announces the Phase 3 SOLUTION Study with Sollpura™ in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results – Additional Study Needed
  23. Are Options Traders Betting on a Big Move in Anthera Pharmaceuticals (ANTH) Stock?
  24. Anthera Announces that the Blisibimod CHABLIS-SC1 Phase 3 Study Did Not Achieve the Primary Endpoint in Patients with Active Systemic Lupus Erythematosus
  25. Anthera Pharmaceuticals Provides Business Update and Reports 2016 Third Quarter Financial Results
  26. Anthera Pharmaceuticals to Provide Business Update and Report 2016 Third Quarter Financial Results on November 4
  27. Anthera Pharmaceuticals Announces Initial $17.0 Million Closing of a Potential $45.33 Million Registered Direct Offering to Biotechnology Value Fund and Rock Springs Capital
  28. Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer
  29. Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results
  30. Anthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod
  31. Anthera Provides Clinical Program Updates for Blisibimod and Sollpura®
  32. Anthera Pharmaceuticals Announces Presentation at JMP Securities Life Sciences Conference
  33. Anthera Pharmaceuticals Announces Presentation at Jefferies Healthcare Conference
  34. Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial Results
  35. Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors